Van Herk Ventures

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

Sensara B.V., located in Rotterdam, the Netherlands, specializes in home healthcare equipment and software through its product Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring their safety and well-being. Sensara utilizes self-learning algorithms to monitor 30 medically verified profiles, providing alerts and advice to family members and caregivers when necessary. Information gathered from various sensors is transmitted to user-friendly apps and interfaces, allowing for better-informed care. The company prioritizes client control over their data and privacy. Sensara's modular product line offers integrated solutions suitable for various living situations, from independent homes to assisted living and nursing facilities, emphasizing the importance of historical data in enhancing future care.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

Ceradis B.V. is a company that specializes in the development and marketing of environmentally friendly solutions for plant nutrition and crop protection products. Founded in 2005 and based in Wageningen, the Netherlands, with an additional office in Bogotá, Colombia, Ceradis also offers crop formulation services. The company's products feature patented formulations that ensure optimal activity of ingredients and provide excellent handling characteristics for users. Ceradis serves the agricultural industry both in the Netherlands and on an international scale.

Medis is a provider of post-processing software for the quantification of cardiovascular images. Medis' mission is to empower medical professionals by providing software that gives them the facts.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Vastned is a retail property company headquartered in the Netherlands, specializing in the leasing of retail properties located in historic city centers across Europe. The company operates through three key segments: Premium City High Street Shops, High Street Shops, and Non-High Street Shops, which includes shopping centers, retail parks, and supermarkets. Vastned's primary focus is on developing its Premium City High Street Shops segment, where it generates significant revenue by leasing properties to a diverse range of tenants, including fashion retailers, dining establishments, and general stores. The majority of its rental income comes from its operations in the Netherlands, France, and Belgium, reflecting its strategic emphasis on these key markets.

Sensara B.V., located in Rotterdam, the Netherlands, specializes in home healthcare equipment and software through its product Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring their safety and well-being. Sensara utilizes self-learning algorithms to monitor 30 medically verified profiles, providing alerts and advice to family members and caregivers when necessary. Information gathered from various sensors is transmitted to user-friendly apps and interfaces, allowing for better-informed care. The company prioritizes client control over their data and privacy. Sensara's modular product line offers integrated solutions suitable for various living situations, from independent homes to assisted living and nursing facilities, emphasizing the importance of historical data in enhancing future care.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

VBHC is a professionally managed real estate company with marquee investors. They are privileged that India's largest home financer, Housing Development Finance Corporation (HDFC), is an anchor equity investor in VBHC.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Isobionics is a company specializing in the production of natural aroma ingredients through a proprietary biotechnology process. It focuses on isoprenoid-based products for the food, beverage, flavor, and fragrance markets. The company develops high-quality and pure flavor and fragrance components, such as citrus oil derivatives like nootkatone and valencene. Using fermentation processes that are free from pesticides and seasonal variability, Isobionics serves various industries, including food, beverage, oral care, and personal care. This innovative approach allows Isobionics to offer customers a consistent sensory experience while maintaining lower production costs.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

VitalNext focuses on developing innovative products that bridge the gap between life sciences and consumer health, specifically targeting the aging population. Recognizing the global significance of healthy aging, the company creates evidence-based products designed to enhance health and well-being as individuals age. Their offerings include advanced medical nutrition aimed at improving body weight and composition in malnourished individuals, with an emphasis on increasing muscle mass. VitalNext commercializes its products through distribution and licensing agreements with specialized business partners, ensuring that their solutions reach those in need. By addressing the growing demand for effective health solutions, VitalNext aims to support people in maintaining good health over extended periods.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide treatment decisions, potentially sparing patients from unnecessary chemotherapy.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide treatment decisions, potentially sparing patients from unnecessary chemotherapy.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide treatment decisions, potentially sparing patients from unnecessary chemotherapy.